Cullinan Therapeutics Files 8-K

TL;DR

Cullinan Therapeutics filed an 8-K on Sept 17, 2024, with updates and exhibits.

AI Summary

Cullinan Therapeutics, Inc. (formerly Cullinan Oncology, Inc.) filed an 8-K on September 17, 2024, reporting on events including a Regulation FD Disclosure and Other Events. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and headquartered in Cambridge, MA.

Why It Matters

This 8-K filing provides an update on Cullinan Therapeutics' corporate activities and regulatory disclosures, which is important for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant negative news or events.

Key Numbers

• 001-39856 — SEC File Number (Identifies the company's filing history with the SEC)
• 81-3879991 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

• Cullinan Therapeutics, Inc. (company) — Registrant
• Cullinan Oncology, Inc. (company) — Former company name
• September 17, 2024 (date) — Date of earliest event reported
• Cambridge, Massachusetts (location) — Company headquarters
• Delaware (location) — State of incorporation

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share CGEM The Nasdaq

Filing Documents

• cgem-20240917.htm (8-K) — 40KB
• cgem-ex99_1.htm (EX-99.1) — 26KB
• 0000950170-24-107011.txt ( ) — 188KB
• cgem-20240917.xsd (EX-101.SCH) — 25KB
• cgem-20240917_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 17, 2024, Cullinan Therapeutics, Inc. (the "Company") issued a press release related to the announcement that the Company received Human Research Ethics Committee ("HREC") approval in Australia to initiate its global Phase 1 clinical trial to evaluate its CD19xCD3 bispecific T cell engager, CLN-978, for the treatment of systemic lupus erythematosus ("SLE"). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this report furnished pursuant to Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report.

01 Other Events

Item 8.01 Other Events. On September 17, 2024, the Company announced it received HREC approval in Australia to initiate its global Phase 1 clinical trial to evaluate CLN-978, the Company's CD19xCD3 bispecific T cell engager, for the treatment of SLE. CLN-978 is a novel CD19 bispecific T cell engager designed to deliver T cell directed potency with off-the-shelf access and convenient dosing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by Cullinan Therapeutics, Inc. on September 17, 2024, furnished herewith 104 Cover page from this Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CULLINAN THERAPEUTICS, INC. Date: September 17, 2024 By: /s/ Mary Kay Fenton Mary Kay Fenton Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR